Sign In
Buy EXEL
$51.34
-0.0100 (-0.0195%)
At Close: Jun 23, 2026
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
03:26pm, Tuesday, 23'rd Jun 2026
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
10:45am, Tuesday, 23'rd Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:41am, Friday, 19'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:51am, Thursday, 18'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis Hits High on Growing Sales, Institutional Inflows
08:25am, Wednesday, 10'th Jun 2026
Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time highs.
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:42pm, Tuesday, 09'th Jun 2026
Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 04'th Jun 2026
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
10:46am, Thursday, 04'th Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
04:02pm, Wednesday, 03'rd Jun 2026
Exelixis, Inc. (EXEL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 03'rd Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 01'st Jun 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) prov
If Decades of History Tell Us Anything, This Biotech Near $50 Is Primed to Skyrocket
10:23am, Thursday, 28'th May 2026
When Wall Street's growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare names, a pattern that has played out across decades of monetary cycles.
